BarbaraProMD

Professor of Medical Oncology, Thomas Jefferson University and Hospitals

Overview of Dr. Pro

Dr. Barbara Pro is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and NewYork-Presbyterian/Columbia University Irving Medical Center. She received her medical degree from Sapienza University of Rome and has been in practice 29 years. She is one of 116 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center and one of 378 doctors at New York-Presbyterian Hospital who specialize in Oncology. She also speaks multiple languages, including Italian and Spanish. She has more than 100 publications and over 500 citings.

Office
161 Fort Washington Ave
New York, NY 10032
Book by Phone+1(929) 334-4069

Education & Training

University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1997 - 2000
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1994 - 1997
Sapienza University of RomeClass of 1988

Certifications & Licensure

NY State Medical License 2022 - 2025
IL State Medical License 2015 - 2023
PA State Medical License 2010 - 2016
TX State Medical License 1999 - 2012

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2013

Clinical Trials

Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide Start of enrollment: 2011 Nov 09
Completed
Phase 1, Phase 2
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL Start of enrollment: 2012 Nov 01
Completed
Phase 3
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 31
Completed
Phase 3
Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2013 Mar 15
Completed
Early Phase 1
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Start of enrollment: 2013 Aug 27
Active, not recruiting
Phase 2
Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy Start of enrollment: 2013 Jul 08
Active, not recruiting
Phase 2
Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2014 Aug 25
Completed
Phase 2
Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma Start of enrollment: 2020 Mar 01
Withdrawn
Phase 2
Join now to see all

Publications & Presentations

PubMed

157 citations
Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma
Issa F. Khouri, Ming S. Lee, Rima M. Saliba, Gu Jun, Luis Fayad
Journal of Clinical Oncology. 2003-12-01
103 citations
Concurrent Administration of High-Dose Rituximab Before and After Autologous Stem-Cell Transplantation for Relapsed Aggressive B-Cell Non-Hodgkin’s Lymphomas
Issa F. Khouri, Rima M. Saliba, Chitra Hosing, Grace Julia Okoroji, Sandra Acholonu
Journal of Clinical Oncology. 2005-04-01
75 citations
Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma.
Barbara Pro, Brian Leber, Mitchell R. Smith, Luis Fayad, Jorge E. Romaguera
British Journal of Haematology. 2008-11-01

Journal Articles

Long‐Term Overall‐ and Progression‐Free Survival After Pentostatin, Cyclophosphamide and Rituximab Therapy for Indolent Non‐Hodgkin Lymphoma
Peter McLaughlin, M Alma Rodriguez, Sattva S Neelapu, Anas Younes, Lei Feng, Michelle A Fanale, Felipe Samaniego, Barbara Pro, Luis Fayad, Fredrick Hagemeister, Jorge ..., British Journal of Haematology
Hemophagocytic Lymphohistiocytosis in Cutaneous T-cell Lymphoma
Jaehyuk Choi, Linda M Serrano, Jason B Kaplan, Barbara Pro, Joan Guitart, JAMA

Abstracts/Posters

Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation
Barbara Pro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Co...
Barbara Pro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas
Barbara Pro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expan...
Barbara Pro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Brief Pembrolizumab(PEM) Monotherapy Results in Complete and Near Complete Responses in the Majority of Untreated Patients with Classical Hodgkin Lymphoma (cHL): A Mul...
Barbara Pro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classi...
Barbara Pro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

New Directions in Treating Peripheral T-Cell Lymphomas: Expert Guidance and Case Discussions
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Time to next treatment in patients with previously treated cutaneous T-cell lymphoma (CTCL) receiving mogamulizumab or vorinostat: A MAVORIC post-hoc analysis.
2019 ASCO Annual Meeting - 6/1/2019
A Phase II Studyof Sequential Pembrolizumab (PEM) Followed By AVD for Frontline Treatment of Classical Hodgkin Lymphoma (CHL): Quantifying Response Following PEM Monot...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Efficacy and Safety of Venetoclax (Ven) + Rituximab (R) or Ven + Bendamustine (B) + R Randomized Versus B + R in Patients (pts) with Relapsed/Refractory (R/R) Follicul...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

Duvelisib Response Rate Encouraging in Phase 2 PRIMO Trial of Patients with r/r PTCLDecember 7th, 2020
Lymphoma Research Foundation's 2019 Swirl: Chicago Raises More Than $130,000June 5th, 2019
Lymphoma Research Foundation to Host Annual Wine Tasting Fundraising Event at the Casino in Chicago, ILMay 1st, 2019
Join now to see all